Evaluating the Prognostic Significance of Immunoscore in Liver Metastases from Colorectal Cancer: A Meta-Analysis Demonstrates the Advantages of Profiling Metastatic Tumors Over Primary Tumors - Scorecard - MDSpire
Advertisement
Evaluating the Prognostic Significance of Immunoscore in Liver Metastases from Colorectal Cancer: A Meta-Analysis Demonstrates the Advantages of Profiling Metastatic Tumors Over Primary Tumors
Clinical Scorecard: Evaluating the Prognostic Significance of Immunoscore in Liver Metastases from Colorectal Cancer: A Meta-Analysis Demonstrates the Advantages of Profiling Metastatic Tumors Over Primary Tumors
At a Glance
Category
Detail
Condition
Key Mechanisms
Immunoscore (IS) quantifies immune cell densities to predict prognosis in CRLM.
Target Population
Care Setting
Key Highlights
CRLM patients have a 5-year survival rate of 16% (source needed).
Radical resection improves survival to 46% compared to 6% for non-surgical treatment.
Immunoscore (IS) is a promising biomarker for prognosis in CRLM.
IS of liver metastases may better predict outcomes than primary tumor IS.
High IS correlates with improved overall survival and disease-free survival (definition needed).
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Regularly evaluate IS levels post-surgery to assess recurrence risk, with specific follow-up intervals.
Risks
Patient & Prescribing Data
Patients with pathologically diagnosed CRLM undergoing surgery.
IS-high patients may benefit from more aggressive treatment strategies.
Clinical Best Practices
Integrate IS assessment into routine clinical practice for CRLM, supported by evidence.
